Literature DB >> 7654070

A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing.

W A van Gool1, H M Evenhuis, C M van Duijn.   

Abstract

The prevalence of clinical signs and neuropathological findings of Alzheimer's disease (AD) is high in Down's syndrome (DS). In the general population, the apolipoprotein E (ApoE) epsilon 4 isoform is an important risk for AD. We studied the allelic frequencies of ApoE in 26 DS cases fulfilling clinical diagnostic criteria for AD and in 26 DS controls matched for age, sex, and premorbid level of mental retardation. A meta-analysis of data available in the literature was used for comparison with allele frequencies in other AD and control populations. ApoE type 2, 3, or 4 allele frequencies were not significantly different in AD-DS cases and DS controls. The ApoE epsilon 4 frequency in DS cases with AD (0.14; CI, 0.06-0.26) was significantly lower than in any other AD population studied so far and it is within the range of nondemented controls from the general population. These findings suggest that ApoE epsilon 4 does not significantly affect the pathogenesis of AD in DS patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654070     DOI: 10.1002/ana.410380215

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Linkage-disequilibrium mapping of disease genes by reconstruction of ancestral haplotypes in founder populations.

Authors:  S K Service; D W Lang; N B Freimer; L A Sandkuijl
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 2.  Epidemiology of the dementias: recent developments and new approaches.

Authors:  C M van Duijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 3.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

4.  Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E.

Authors:  A A Golabek; E Kida; M Walus; C Perez; T Wisniewski; C Soto
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

5.  Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Authors:  Troy T Rohn; Katie L McCarty; Julia E Love; Elizabeth Head
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-12-08

6.  Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome.

Authors:  V P Prasher; S G Sajith; S D Rees; A Patel; S Tewari; N Schupf; W B Zigman
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

Review 7.  Psychosocial Risk Factors for Alzheimer's Disease in Patients with Down Syndrome and Their Association with Brain Changes: A Narrative Review.

Authors:  Osama Hamadelseed; Ibrahim H Elkhidir; Thomas Skutella
Journal:  Neurol Ther       Date:  2022-05-21

8.  Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome.

Authors:  Ashok Patel; Simon D Rees; M Ann Kelly; Stephen C Bain; Anthony H Barnett; Anisha Prasher; Humaria Arshad; Vee P Prasher
Journal:  BMC Res Notes       Date:  2014-01-17

9.  Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome.

Authors:  Emma L Jones; Kin Mok; Marisa Hanney; Denise Harold; Rebecca Sims; Julie Williams; Clive Ballard
Journal:  Neurobiol Aging       Date:  2013-04-18       Impact factor: 4.673

10.  The Association between Sex and Risk of Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Pooja Girish Mhatre; Joseph H Lee; Deborah Pang; Warren B Zigman; Benjamin Tycko; Sharon J Krinsky-McHale; Yuchen Yang; Wayne Silverman; Nicole Schupf
Journal:  J Clin Med       Date:  2021-07-01       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.